The average one-year price target for Iterum Therapeutics (NasdaqCM:ITRM) has been revised to 6.63 / share. This is an increase of 550.00% from the prior estimate of 1.02 dated December 13, 2021. The ...
・PMGC Holdings said Friday that its unit, NorthStrive Biosciences, amended a deal with MOA Life Plus to run human trials for EL-22 and EL-32, targeting muscle and lean mass preservation. ・Iterum ...
Iterum Therapeutics ( (ITRM)) has issued an announcement. On December 11, 2025, Iterum Therapeutics received a notification from Nasdaq indicating that it no longer meets the listing requirements due ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results